EXHIBIT 99

            OMNICOMM SYSTEMS, INC. SECURES FINANCING OF $2 MILLION

MIAMI--(BWHealthWire)--September 25, 2001--OmniComm(SM) Systems, Inc.
(OTCBB:OMCM- news) of Miami, Florida, a leading provider of Web-based clinical
trial solutions for the pharmaceutical and healthcare industries today announces
that it has completed a $2 million equity private placement. Commonwealth
Associates, L.P. of New York acted as placement agent and ComVest Venture
Partners, L.P. acted as lead investor in the round.

The private placement is comprised of  20 units, consisting of the Company's 8%
Series B Convertible Preferred Stock and stock warrants.  The units  are each
convertible into 400,000 shares of the Company's common stock, and five year
warrants to purchase 400,000 shares of the Company's Common Stock.
Approximately $330,000 of existing debt of the Company was converted into the
financing.

Dr. David Ginsberg, CEO of OmniComm remarked, "Commonwealth's financial
commitment will allow us to continue to execute our business plan."  Ginsberg
added, "We believe our technology will continue to gain wide acceptance in the
clinical research industry.  Our clients are experiencing dramatic results,
especially in the area of moving their drugs through the development process
faster, with cleaner, more accurate data."

About OmniComm

OmniComm(SM) (http://www.omnicomm.com) has developed a distinctive business
model designed to integrate health information systems and coordinate the
processes necessary to utilize health information. OmniComm is uniquely
positioned to participate in and benefit from the burgeoning growth in the
pharmaceutical, biotech, and medical device industry. OmniComm has developed an
Internet-based approach to integrate the significant components -- data
collection, validation, and reporting -- of the clinical trial process into a
seamless process that is considerably less expensive, faster and better than the
conventional method of conducting clinical trials.

The TrialMaster(R) application (http://www.trialmaster.com) provides trial
sponsors with a Web-based data and trial management solution that greatly
increases the efficiency, security and integrity of clinical research and thus
significantly reduces the time and expense involved in conducting a trial.

Statements about OmniComm's future expectations, including without limitation,
future revenues and earnings, plans and objectives for the future operations,
future agreements, future economic performance, operations and all other
statements in this press release other than historical facts are "forward-
looking statements'' within the meaning of Section 27A of the Securities Act of
1933, Section 21E of the Securities Exchange Act of 1934, and as that term is
defined in the Private Securities Litigation Reform Act of 1995. OmniComm
intends that such forward-looking statements be subject to the Safe Harbors
created thereby. Since these statements involve risks and uncertainties,
including but not limited to economic, competitive, governmental, contractual
and technological factors affecting OmniComm's operations, markets and
profitability, actual results could differ materially and adversely from the
expected results.

______________
Contact:

OmniComm Systems, Inc., Miami, Florida
Peter Lash, JD 305/448-4700
invr@omnicomm.com